Dimethyl fumarate and its esters: A drug with broad clinical utility?
journal contributionposted on 2020-11-19, 05:46 authored by S Kourakis, CA Timpani, Judy de HaanJudy de Haan, N Gueven, D Fischer, E Rybalka
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Fumaric acid esters (FAEs) are small molecules with anti‐oxidative, anti‐inflammatory and immune‐modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing‐Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune‐mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first‐line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated.
This research received no external funding (funding was provided by Victoria University and University Children's Hospital Basel commercialization partnership scheme).
Article NumberARTN 306
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
CategoriesNo categories selected
Science & TechnologyLife Sciences & BiomedicinePharmacology & Pharmacyclinical applicationdimethyl fumaratediseasefumaric acid estersoxidative stressinflammationNrf2OBSTRUCTIVE SLEEP-APNEAREMITTING MULTIPLE-SCLEROSISPLACEBO-CONTROLLED PHASE-3CHRONIC PLAQUE PSORIASISNF-KAPPA-BACID ESTERSOXIDATIVE STRESSNRF2 ACTIVATORDOUBLE-BLINDDISEASE PROGRESSION